🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

545 results for “B.” Clear

  1. Avapritinib, Avapritinib, Avapritinib Placebo Tablets

    Blueprint Medicines (Netherlands) B.V.

    Indolent Systemic Mastocytosis (ISM)

    phase 2 small molecule active

    1 trial

  2. BMS-955176

    ViiV Healthcare B.V.

    HIV Infections

    phase 2 small molecule terminated

    1 trial

  3. Bivamelagon

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 2 small molecule active

    1 trial

  4. Byooviz 10 mg/ml solution for injection

    Samsung Bioepis NL B.V.

    Neovascular Age-Related Macular Degeneration (AMD), Macular Oedema Secondary to Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV)

    phase 2 small molecule active

    1 trial

  5. CAMPTO 20 mg/mL concentrate for solution for infusion, Futibatinib, Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion, FLUOROURACIL, CISPLATIN, OXALIPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Solid Tumors

    phase 2 small molecule active

    1 trial

  6. CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib

    Pharming Technologies B.V.

    primary immunodeficiency

    phase 2 small molecule active

    1 trial

  7. CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib

    Pharming Technologies B.V.

    Common variable immunodeficiency

    phase 2 small molecule active

    1 trial

  8. CEP-18770

    Teva Generics B.V

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  9. Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Avastin 25 mg/ml concentrate for solution for infusion., Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Zejula 100 mg hard capsules, Zejula 100 mg hard capsules, Zejula 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion.

    TESARO Bio Netherlands B.V.

    Ovarian Neoplasms

    phase 2 small molecule active

    1 trial

  10. Carfilzomib 56 MG [Kyprolis]

    Samsung Bioepis NL B.V.

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  11. Cefiderocol

    Shionogi B.V.

    Gram-negative Bacterial Infections

    phase 2 small molecule completed

    1 trial

  12. Chlorid sodný B. Braun 0,9 % infuzní roztok, DUOFAG

    Lacuna Pharma Pty Ltd

    Surgical wound infection/dehiscence caused by S. aureus and/or P. aeruginosa colonization

    phase 2 small molecule active

    1 trial

  13. Coronary Artery Stenting

    Medtronic BioPharma B.V.

    Coronary Artery Disease

    phase 2 other completed

    1 trial

  14. Cyclophosphamide

    Iovance Biotherapeutics B.V.

    Clinical Stage IV Cutaneous Melanoma AJCC v8

    phase 2 small molecule completed

    1 trial

  15. Cyclophosphamide

    Iovance Biotherapeutics B.V.

    Metastatic Bladder Urothelial Carcinoma

    phase 2 small molecule terminated

    1 trial

  16. Diuretics

    Rhythm Pharmaceuticals Netherlands B.V.

    Heart Failure

    phase 2 small molecule completed

    1 trial

  17. Docetaxel + Sunitinib

    Samsung Bioepis NL B.V.

    Advanced Gastric Cancer

    phase 2 small molecule completed

    1 trial

  18. E7 TCR-T cells

    Iovance Biotherapeutics B.V.

    Cervical Cancer

    phase 2 mab active

    1 trial

  19. E7 TCR-T cells

    Iovance Biotherapeutics B.V.

    HPV-Associated Cervical Carcinoma

    phase 2 mab active

    1 trial

  20. Enasidenib

    Agios Netherlands B.V.

    Hematologic Neoplasms

    phase 2 small molecule completed

    1 trial

  21. Evogliptin

    Samsung Bioepis NL B.V.

    Type2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  22. FLUDARABINE PHOSPHATE, ALDESLEUKIN, LN-145, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE

    Iovance Biotherapeutics B.V.

    Recurrent, metastatic, or persistent Cervical Carcinoma

    phase 2 small molecule active

    1 trial

  23. Fludarabine Teva 25 mg/ml solution à diluer pour injection ou perfusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, LN-145, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cyclophosphamide Injection 1 g., Fludarabine 50mg Powder For Solution For Injection Or Infusion, Endoxan, Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор, Fludarabinefosfaat – PCH 25 mg/ml, concentraat voor oplossing voor injectie/infusie, FLUDARAB

    Iovance Biotherapeutics B.V.

    Metastatic Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. Futibatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Advanced or Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources